Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

Mariko Harada‐Shiba; Michael H. Davdison; Marc Ditmarsch; Andrew Hsieh; Erin Wuerdeman; Douglas Kling; A. Nield; Mary R. Dicklin; Akitaka Nakata; Atsushi Sueyoshi; Satoshi Kuroyanagi; John J.P. Kastelein

doi:10.5551/jat.64828

April 2, 2024Journal of Atherosclerosis and ThrombosisOpen Access

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy, safety, and tolerability of obicetrapib when administered as an adjunct to stable statin therapy in an East Asian cohort.
Randomized phase 2 clinical trial evaluating obicetrapib as an adjunct to background stable statin therapy.
Conducted in Japanese subjects to assess lipid-lowering parameters, tolerability, and safety outcomes.
Obicetrapib functions as a selective cholesteryl ester transfer protein (CETP) inhibitor to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB).
Trial established the safety, tolerability, and efficacy profile of obicetrapib in an Asian-Pacific regional population on background statin therapy.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized phase 2 trial demonstrates the efficacy and tolerability of obicetrapib in Japanese adults, indicating broad therapeutic potential across diverse populations.

Abstract

Aims: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), when taken as monotherapy and in combination with ezetimibe on a background of statins, in clinical trials predominantly conducted in Northern European/Caucasian participants. We characterized the efficacy, safety, and tolerability of obicetrapib within an Asian-Pacific region population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Harada‐Shiba et al. (2024) studied this question.

synapsesocial.com/papers/69fd7a139f13d6d4f45094d3 https://doi.org/10.5551/jat.64828

View Full Paper

Ask AI

Bookmark

Share

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading